Background-In the heart with acute myocardial infarction, production of prostaglandin (PG) E 2 increases significantly.
A cute myocardial infarction (AMI) is still a leading cause of death in developed countries, and it is usually caused by acute thrombotic occlusion of the coronary artery that has become atherosclerotic. The underlying pathophysiology of AMI is ischemia-reperfusion (I/R) injury of the heart. During cardiac I/R, a variety of mediators, such as adenosine, 1 endothelin, 2 and nitric oxide, 3 are produced in the heart and have all been suggested as modulating the course of cardiac I/R injury. Recently, cyclooxygenase (COX)-2, a ratelimiting enzyme for the synthesis of prostaglandins (PGs), has been reported to be induced in the heart during I/R. 4 This result is consistent with the fact that production of PGE 2 in the heart increases significantly during ischemia, 5, 6 suggesting that it has an important role in cardiac I/R injury. The contribution of endogenous PGE 2 to cardiac I/R injury, however, remains unknown. PGE 2 exerts its action through the specific receptor subtypes encoded by different genes called EPs: EP 1 , EP 2 , EP 3 , and EP 4 , all of which belong to the family of G protein-coupled receptors but show different signaling. 7 EP 1 couples to G q and raises intracellular Ca 2ϩ concentration. EP 2 and EP 4 couple to G s and raise intracellular cAMP concentration ([cAMP] i ). In contrast, EP 3 couples to G i and inhibits the increase in [cAMP] i . When examined with Northern blot analysis, the heart shows expression of several kinds of EPs. Although the expression levels of the mRNAs for each EP vary among the species studied, a high expression level of the EP 4 mRNA has been reported in the hearts of several species, including humans. 8 -10 There have been no reports, however, on the role of the EP 4 -mediated signaling in the heart.
To clarify the role of PGE 2 via EP 4 in cardiac I/R injury, we used mice lacking EP 4 (EP 4 Ϫ/Ϫ mice) 11 and also used recently developed EP 4 -specific agonists. 12, 13 We found that endogenous PGE 2 had a cardioprotective effect against I/R injury via EP 4 both in vivo and in vitro. Furthermore, we demonstrated that an exogenous EP 4 agonist protected the heart from I/R injury in vivo.
Methods

Mice
Generation and maintenance of EP 4 Ϫ/Ϫ mice has been reported. 11 
Most EP 4
Ϫ/Ϫ mice die postnatally as a result of patent ductus arteriosus and do not survive at all in the C57BL/6 background. Therefore, F2 progenies of surviving EP 4 Ϫ/Ϫ mice and their wild-type littermates were maintained independently in a mixed genetic background of 129/Ola and C57BL/6. All experiments, which were approved by the Asahikawa Medical College Committee on Animal Research, were performed in 10-to 16-week-old male mice.
Reverse Transcription-Polymerase Chain Reaction
To determine the expression levels of EP mRNAs, we prepared total RNA from the cardiac ventricles of adult mice and from the cultured fetal noncardiomyocytes using Isogen (Nippon Gene) and performed reverse transcription-polymerase chain reaction (RT-PCR) and competitive RT-PCR as reported. 14 We also prepared total RNA from the cardiomyocytes, which were isolated from the ventricles of adult mice according to the reported method. 15
Murine Model of AMI
We used a murine model of AMI to examine the role of both endogenous PGE 2 and an exogenous EP 4 agonist in cardiac I/R injury in vivo, in which the left anterior descending coronary artery (LAD) was occluded for 1 hour, followed by 24 hours of reperfusion, as reported. 16 When examining the effect of an exogenously applied agonist on cardiac I/R injury, we injected 4819-CD (300 g/kg SC) subcutaneously 1 hour before or 50 minutes after occlusion of the LAD. We determined infarct size, size of area at risk (AAR), and left ventricular size (LVS) as reported. 16 
Heart Perfusion Model
We examined the role of endogenous PGE 2 in cardiac I/R injury in vitro by use of a heart perfusion model as reported. 16 In short, we perfused excised hearts according to the Langendorff technique. After a stabilization period, the hearts were subjected to 40 minutes of global ischemia followed by 40 minutes of reperfusion. The developed and diastolic tensions, creatine kinase (CK) release, and coronary flow rate were monitored during the I/R period.
Cell Cultures
We performed cultures of cardiomyocytes and noncardiomyocytes as reported, 17 with minor modifications. In short, ventricles from 18-to 20-day fetal mice were treated with a solution containing collagenase. The released cells were harvested and filtered through a nylon mesh, then the cells were preplated into a dish to separate the cardiomyocytes from the noncardiomyocytes. Unattached cardiomyocytes were harvested, resuspended in a culture medium, and plated for the examinations of cAMP accumulation. Attached noncardiomyocytes were grown to near confluence and used for a similar examination.
Measurements of cAMP Accumulation
The cardiomyocytes were stimulated with AE1-329 or vehicle for 30 minutes at 37°C in DME/F-12 medium containing ITS-X (Invitrogen), 10 mol/L indomethacin, and 1 mmol/L 3-isobutyl-1methylxanthine (Sigma-Aldrich). The noncardiomyocytes were stimulated similarly in DME/F-12 medium containing 10 mol/L indomethacin and 1 mmol/L 3-isobutyl-1-methylxanthine. The intracellular cAMP contents were measured as reported. 14 We determined the protein contents of the cells by use of a BCA protein assay kit (Pierce Chemical).
Measurement of Blood Pressure and Heart Rate
Blood pressure and heart rate of conscious mice were measured by a tail-cuff method (BP-98A, Softron).
Drugs
AE1-329 and 4819-CD, selective EP 4 agonists, were kindly donated by Ono Pharmaceuticals.
Statistical Analysis
All data are expressed as meanϮSEM. Statistical analyses and graphing of the data were performed as reported. 18
Results
Expression of mRNAs for the EPs in the Cardiac Ventricle
We first examined which subtypes of the EPs were expressed in the cardiac ventricle of adult wild-type mice by RT-PCR, because the cardiac ventricle is the main site of cardiac I/R injury. We found expression of the mRNAs for EP 2 , EP 3 , and EP 4 but not for EP 1 (Figure 1A ). The expression levels of the mRNAs determined by competitive RT-PCR were 54.3Ϯ7.4, 13.2Ϯ2.3, and 1.3Ϯ0.5 copies/ng total RNA for EP 4 , EP 3 , and EP 2 , respectively, suggesting that EP 4 is most abundantly expressed among the EPs ( Figure 1B ). The expression levels of EP 4 mRNA in cardiomyocytes and noncardiomyocytes were found to be 19.1Ϯ3.9 and 62.6Ϯ18.5 copies/ng total RNA, respectively, indicating high expression levels of the EP 4 mRNA in both cardiomyocytes and noncardiomyocytes. On the basis of these results, we performed the following experiments to determine whether PGE 2 protects the heart from I/R injury via EP 4 .
Endogenous PGE 2 Protects the Heart From I/R Injury In Vivo
We examined the role of endogenous PGE 2 in cardiac I/R injury using a murine model of AMI. There were no signif- icant differences in basal heart weight and morphology between wild-type and EP 4 Ϫ/Ϫ mice (data not shown). Representative photographs showing the transverse sections of wild-type and EP 4 Ϫ/Ϫ hearts after I/R are shown in Figure 2A . In an EP 4 Ϫ/Ϫ heart, the white necrotic area was markedly enlarged compared with that in a wild-type heart. Summary data for the ratios of infarct size versus size of AAR and AAR versus LVS are shown in Figure 2B . In EP 4 Ϫ/Ϫ mice, the infarct size was significantly increased compared with wildtype mice. The infarct sizes as a percentage of AAR were 38.4Ϯ2.8% and 52.1Ϯ6.0% in wild-type and EP 4 Ϫ/Ϫ mice, respectively, showing that relative increase in infarct size in EP 4 Ϫ/Ϫ mice was 37% greater than that of wild-type mice. In both wild-type and EP 4 Ϫ/Ϫ hearts, however, AAR as a percentage of LVS was similar, showing no difference in the size of areas perfused by the LAD. Mortalities of mice during I/R were 23.8% and 35.0% in wild-type and EP 4 Ϫ/Ϫ mice, respectively. These results clearly show that endogenous PGE 2 protects the heart from I/R injury via EP 4 in vivo. There were no significant differences in blood pressure or heart rate under resting condition between wild-type and EP 4 Ϫ/Ϫ mice. In wild-type mice, systolic blood pressure, diastolic blood pressure, and heart rate were 106Ϯ5 mm Hg, 73Ϯ3 mm Hg, and 601Ϯ36 bpm, respectively (nϭ6). In EP 4 Ϫ/Ϫ mice, these were 114Ϯ3 mm Hg, 72Ϯ5 mm Hg, and 566Ϯ33 bpm, respectively (nϭ7).
Endogenous PGE 2 Protects the Heart From I/R Injury In Vitro
Using excised murine hearts perfused according to the Langendorff technique, we determined whether the EP 4 -mediated cardioprotective effect of PGE 2 also works in the absence of blood constituents, such as humoral factors and blood cells. Before ischemia, there were no significant differences in diastolic tension or developed tension between wild-type and EP 4 Ϫ/Ϫ hearts (data not shown). Global ischemia markedly decreased developed tension and caused a gradual rise in diastolic tension in both groups of hearts to a similar extent. In wild-type hearts, developed tension recovered up to 90% of the preischemic value within 5 minutes from the start of reperfusion and then gradually declined to 70% of the preischemic value and remained fairly constant. In EP 4
Ϫ/Ϫ hearts, however, recovery of developed tension was significantly suppressed compared with that of wild-type hearts and was 58% of the preischemic value at a steady state ( Figure  3A ). In contrast, diastolic tension rose during 40 minutes of ischemia and reached, at the end of ischemia, up to 300% of preischemic values in wild-type and EP 4 Ϫ/Ϫ hearts. In wildtype hearts, diastolic tension then declined quickly during reperfusion and reached a level of 125% of the preischemic value. In EP 4 Ϫ/Ϫ hearts, however, recovery of diastolic tension was significantly delayed compared with that of wild-type hearts ( Figure 3B ). These results indicate that there was a greater degree of functional damage to the myocardium in EP 4 Ϫ/Ϫ hearts compared with wild-type hearts. In accordance with this result, release of CK from the heart increased significantly during the reperfusion period in EP 4 Ϫ/Ϫ hearts compared with wild-type hearts ( Figure 3C ), suggesting that endogenous PGE 2 had a protective effect on the cell damage induced by I/R. Within 5 minutes from the start of reperfusion, coronary flow rate was significantly higher than the baseline rate in both groups, showing that there was reactive vasodilation during the early period of reperfusion. 16 There was no significant difference, however, in the coronary flow rate between wild-type and EP 4 Ϫ/Ϫ hearts during the reperfusion period ( Figure 3D ), suggesting that the cardioprotective effects of PGE 2 via EP 4 are independent of its vasodilatory action. 19
AE1-329 Increases [cAMP] i in Both Cardiomyocytes and Noncardiomyocytes
To clarify whether PGE 2 acts on cardiomyocytes and/or noncardiomyocytes via EP 4 , we examined the effect of AE1-329, a recently developed agonist specific for EP 4 , 12 on [cAMP] i in these cells. In noncardiomyocytes, AE1-329 increased [cAMP] i in a concentration-dependent manner with an EC 50 value of 33.0Ϯ0.5 nmol/L, plateauing at 1 mol/L to a value of 11.8-fold above control values ( Figure 4A ). The effect of AE1-329 disappeared completely in noncardiomyocytes derived from EP 4 Ϫ/Ϫ hearts, indicating that the effect was mediated by EP 4 . In cardiomyocytes from wild-type hearts, AE1-329 at 10 mol/L induced a slight but significant Ϫ/Ϫ heart after I/R is larger than that in wild-type heart. A, Representative photomicrographs of horizontal section of left ventricle from wild-type and EP 4 Ϫ/Ϫ mice after I/R. Tissue area stained blue represents nonischemic area. Within ischemic area, tissue area stained red is still alive, and tissue area appearing pale white is necrotic. B, Infarct size after I/R in wild-type (▫) and EP 4 Ϫ/Ϫ (Ⅲ) mice. Infarct size and AAR as a percentage of AAR and LVS, respectively, are presented. *PϽ0.05 vs wild-type group. nϭ10. increase in [cAMP] i , although it did not increase [cAMP] i in cardiomyocytes from EP 4 Ϫ/Ϫ hearts ( Figure 4B ). These results show the possibility that both cardiomyocytes and noncardiomyocytes are the target cells of PGE 2 via EP 4 .
An EP 4 Agonist Shows Cardioprotective Action in I/R Injury In Vivo
Finally, we investigated whether the activation of EP 4 by a specific agonist could attenuate cardiac I/R injury in vivo. To activate EP 4 , we used 4819-CD, a novel agonist for EP 4 , 13 which has been developed for in vivo use as a kind of prodrug and liberates an active metabolite in the circulation. We injected 4819-CD (300 g/kg SC) 1 hour before occlusion of the LAD. In wild-type mice, the EP 4 agonist reduced the infarct size significantly (42% reduction compared with those in the absence of the agonist), whereas it did not reduce the infarct size in EP 4 Ϫ/Ϫ mice, indicating that the cardioprotective effect of 4819-CD was mediated by EP 4 (Figure 5 ). Moreover, when injected 50 minutes after occlusion of the LAD, 4819-CD showed a cardioprotective effect almost identical to that seen when injected before the occlusion of the LAD, indicating the therapeutic potency of the drug. At the dose used, 4819-CD did not affect blood pressure or heart rate in wild-type mice (Table) , indicating that the cardioprotective effect of 4819-CD was independent of its effect on hemodynamics.
Discussion
Recent studies have shown upregulation of COX-2 and increased PGE 2 synthesis in the heart during I/R, suggesting that PGE 2 plays some role in cardiac I/R injury. To elucidate this role, we first examined which subtypes of the PGE 2 receptors are expressed. We detected mRNAs for EP 2 , EP 3 , and EP 4 in adult murine ventricles. Among the EPs, the EP 4 mRNA showed by far the highest expression level (Figure 1 ). This result is in good agreement with previous reports showing the high expression level of EP 4 mRNA in the heart from various species, suggesting that EP 4 mediates the effect of PGE 2 in the heart. The role of PGE 2 in I/R injury, however, remains unknown, primarily because of lack of antagonists specific for EP 4 . Until recently, there were no specific agonists for EP 4 , but now agonists showing high specificities to EP 4 are available. In the present study, to clarify the role of PGE 2 in cardiac I/R injury, we used EP 4 Ϫ/Ϫ mice and these EP 4 agonists.
The present study provided direct evidence that EP 4 deficiency significantly aggravates cardiac I/R injury in vivo (Figure 2 ). To the best of our knowledge, this is the first report showing that endogenous PGE 2 is able to attenuate cardiac I/R injury and that the effect of PGE 2 is mediated by EP 4 . Because there is significant production of PGE 2 during I/R and abundant expression of the EP 4 mRNA in the heart, PGE 2 should exert its cardioprotective action by acting directly on the cardiac tissue. PGE 2 , however, has a potent vasodilatory action 19 and also an inhibitory effect on the neutrophil function 20 via EP 4 , both of which might contribute to the EP 4 -mediated cardioprotective effect of PGE 2 . Therefore, to examine further whether the EP 4 -mediated cardioprotective effect of PGE 2 depends on the effects on the neutrophils and/or vasculatures, we used Langendorff hearts. In this model, EP 4 Ϫ/Ϫ hearts developed a greater degree of myocar- dial injury than wild-type hearts, indicating that PGE 2 could attenuate I/R injury by acting directly on the cardiac tissue via EP 4 in the absence of blood constituents (Figure 3 ). Furthermore, there was no difference in coronary flow rate during I/R between EP 4
Ϫ/Ϫ and wild-type hearts ( Figure 3D ), precluding the EP 4 -mediated vasodilatory action of PGE 2 from its cardioprotective action. This result clearly indicates that the cardioprotective action of PGE 2 is independent of its actions on blood constituents and vasculatures, although the possibility of some contribution by these actions to cardioprotection in vivo could not be ruled out by the present study.
The present study also revealed the target cells of PGE 2 . AE1-329, an EP 4 agonist, increased [cAMP] i in both cardiomyocytes and noncardiomyocytes from wild-type mice but not in those from EP 4 Ϫ/Ϫ mice, indicating that PGE 2 acts on these cells via EP 4 (Figure 4 ). Although it is not known how the rise in [cAMP] i in these cells causes the cardioprotection during I/R, several reports suggest possible mechanisms. First, the increase in [cAMP] i inhibits secretion of tumor necrosis factor (TNF)-␣ by inhibiting the activation of nuclear factor-B and stimulates secretion of interleukin (IL)-10 by stimulating the cAMP-responsive nuclear factors in several types of cells. 21 In agreement with these findings, PGE 2 inhibits the production of TNF-␣ and stimulates the production of IL-10 via EP 4 in macrophages. 22 TNF-␣ is known to be produced during cardiac I/R by both cardiomyocytes and noncardiomyocytes 23 and to aggravate cardiac injury. 24 In contrast, endogenous IL-10 has been reported to protect the heart from I/R injury. 25 These results suggest that PGE 2 may protect the heart by regulating the production of these cytokines. Second, when stimulated by PGE 2 , the mesenchymal fibroblastic cell, a major cell type among the noncardiomyocytes, releases hepatocyte growth factor (HGF), a factor showing a growth-promoting effect on various types of cells. In addition, endogenous HGF exerts a cardioprotective action against I/R injury. 26 These results suggest that PGE 2 could stimulate the production of HGF in noncardiomyocytes during cardiac I/R and that this action may explain the cardioprotective effect of PGE 2 at least in part. The precise mechanism of the EP 4 -mediated signaling leading to cardioprotection, however, remains to be clarified.
The increase in [cAMP] i during cardiac I/R, such as caused by stimulation of ␤ 1 -adrenergic receptor, is generally thought Ϫ/Ϫ group) or 10 mol/L of AE1-329 (Ⅲ, nϭ5 for wild-type group and nϭ4 for EP 4 Ϫ/Ϫ group). *PϽ0.05 vs control group. to be deleterious to cardiomyocytes and leads to increases in cardiac work and energy consumption, resulting in severe cardiac injury. Therefore, the present results of the EP 4mediated stimulatory effect of PGE 2 on adenylate cyclase in cardiomyocytes apparently disagree with the EP 4 -mediated cardioprotective action of PGE 2 . As to the effect of the increase in [cAMP] i , however, there are several interesting reports suggesting the subcellular compartmentalization of cAMP, leading to its different actions within cardiomyocytes. 27 The ␤ 1 -adrenergic receptor localizes mainly in the noncaveolin domain, and its stimulation increases [cAMP] i in a particular fraction of cardiomyocytes, leading to a positive inotropic action. 28 In contrast, the ␤ 2 -adrenergic receptor localizes mainly in the caveolin-rich domain, and its stimulation increases [cAMP] i in a soluble fraction of cardiomyocytes. 28 The ␤ 2 -agonists, however, do not produce the positive inotropic action. 29 These results suggest that the EP 4mediated increase in [cAMP] i takes place in the soluble fraction of cardiomyocytes. In support of this suggestion, a previous study has shown that PGE 2 does not produce the positive inotropic action, whereas it increased [cAMP] i in the soluble fraction of cardiomyocytes. 30 Another important finding in the present study was that an exogenously applied agonist for EP 4 significantly reduced the infarct size and that this effect was mediated by EP 4 . Furthermore, it is noteworthy that 4819-CD showed a potent cardioprotective effect not only when administered before occlusion of the LAD but also when administered after prolonged (50 minutes) occlusion of the LAD. According to previous findings, various anti-ischemic drugs, such as ␤-adrenoceptor antagonists and Ca 2ϩ channel blockers, are effective when given before ischemia but not after. 33, 34 Therefore, EP 4 agonists may be a novel type of anti-ischemic agent retaining effectiveness when given after an ischemic event had already occurred. This result strongly indicates that EP 4 agonists are promising candidates as therapeutics for ischemic heart diseases such as AMI.
Effects of 4819-CD on Heart Rate and Blood Pressure in Wild-Type Mice
To the best of our knowledge, this is the first report verifying that the selective activation of an EP subtype can protect the heart from I/R injury. There have been several reports suggesting a cardioprotective effect of EP 3 agonists against I/R injury when applied exogenously. 35, 36 These effects, however, have not been verified as being mediated by the EP 3 , because of lack of an EP 3 antagonist. Taking into consideration that there is abundant expression of mRNA for EP 4 compared with that for EP 3 in the heart and that there is an apparent cardioprotective role of EP 4 against I/R injury as shown in this study, the contribution of EP 3 toward cardioprotection in I/R injury should be clarified in future studies.
In conclusion, we have demonstrated that there is significant aggravation of cardiac I/R injury in EP 4 Ϫ/Ϫ mice both in vivo and in vitro, providing strong evidence that endogenous PGE 2 protects the heart from I/R injury via EP 4 . Therefore, inhibitors of cyclooxygenase, such as aspirin and indomethacin, may exacerbate ischemic heart disease, even though they have been widely used for the prevention and treatment of inflammation, thrombosis, and colon cancer. Furthermore, an exogenous EP 4 agonist at a dose producing no hemodynamic effect showed a potent cardioprotective action against I/R injury in vivo, suggesting that EP 4 agonists will be useful for treatment of the ischemic heart disease.
